Models for early chemoprevention trials in breast cancer

Hematology/Oncology Clinics of North America

Volumn 12, Issue 5, 1998, Pages 993-1017

  Fabian, C J ^a   Kimler, B F ^a   Elledge, R M ^a   Grizzle, W E ^a   Beenken, S W ^a   Ward, J H ^a  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARZOXIFENE; CYCLINE; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; HERMES ANTIGEN; PROGESTERONE RECEPTOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN RECEPTOR; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA2; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ASPIRATION BIOPSY; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; HUMAN; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW;

EID: 0031719608     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70038-1     Document Type: Article

References (150)

1. D.J. Allan A. Howell S.A. Roberts Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast J Pathol 167 1992 25 32
2. D.C. Allred G.M. Clark R. Molina Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer Hum Pathol 23 1992 974 979
3. D.C. Allred P. O'Connell S.A.W. Fuqua Biomarkers of early breast neoplasia J Cell Biochem 17G 1993 125 131
4. Diagnostic cytopathology by membrane filter. Application Bulletin 100R, Gelman Sciences, Ann Arbor, 1984, pp 11–16
5. M.M. Arnold S. Srivastava J. Fredenburgh Effect of fixation and tissue processing on immunohistochemical demonstration on specific antigens Biotech Histochem 71 1996 224 230
6. P.P. Athanassiadou S.Z. Veneti K.A. Kyrkou Presence of epidermal growth factor receptor in breast smears of cyst fluids: Relationship to electrolyte ratios and pH concentration Cancer Detect Prev 16 1992 113 118
7. D.E. Ayer C.D. Laherty Q.A. Lawrence A.P. Armstrong Mad proteins contain a dominant transcription repression domain Mol Cell Biol 16 1996 5772
8. J.W. Bacus J.V. Bacus Quality control in image cytometry: DNA ploidy J Cell Biochem 19 suppl G 1994 153 164
9. J.W. Bacus J.V. Bacus A method of correcting DNA ploidy measurements in tissue sections Mod Pathol 7 1994 652 664
10. R.C. Bargou P.T. Daniel M.Y. Mapara Expression of the bcl-2 gene family in normal and malignant breast tissue: Low bax-alpha expression in tumor cells correlates with resistance towards apoptosis Int J Cancer 60 1995 854 859
11. S.B. Baylin J.G. Herman J.R. Graff Alterations in DNA methylation: A fundamental aspect of neoplasia Adv Cancer Res 72 1998 141 196
12. N. Bertin P. Clezardin R. Kubiak Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: Correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia Cancer Res 57 1997 396 399
13. C. Binder D. Marx L. Binder Expression of bax in relation to bcl-2 and other predictive parameters in breast cancer Ann Oncol 7 1996 129 133
14. I.V. Boiko M.F. Mitchell D.K. Pandey DNA image cytometric measurement as a surrogate end point biomarker in a Phase I trial of αΦdifluoromethylornithine for cervical intraepithelial neoplasia Cancer Epidemiol Biomarkers Prev 6 1997 849 855
15. C.W. Boone J.W. Bacus J.V. Bacus Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate end points for clinical trials Proc Soc Exp Biol Med 216 1997 151 165
16. L.F. Brown B. Berse R.W. Jackman Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer Hum Pathol 26 1995 86 91
17. P.F. Bruning J. Van Doorn J.M. Bonfrer Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer Int J Cancer 62 1995 266 270
18. C. Byrne Studying mammographic density: Implications for understanding breast cancer J Natl Cancer Inst 89 1997 531 533
19. E. Cassano G. Coopmans deYoldi Mammographic patterns in breast cancer chemoprevention with fenretinide (4-HPR) Eur J Cancer 29A 1993 2161 2163
20. R.B. Clarke A. Howell E. Anderson Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone Br J Cancer 75 1997 251 257
21. R.B. Clarke I.J. Laidlaw L.J. Jones Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status Br J Cancer 67 1993 606 611
22. P. Clezardin L. Frappart M. Clerget Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast Cancer Res 53 1993 1421 1430
23. A. Costa A. Decensi A. DePalo Breast cancer chemoprevention with retinoids and tamoxifen Proc Am Assoc Cancer Res 37 1996 655
24. J.D. Crissman D.W. Visscher J. Kubus Image cytophotometric DNA analysis of atypical hyperplasias and intraductal carcinomas of the breast Arch Pathol Lab Med 114 1990 1249 1253
25. A.M. Davidoff B.J. Kerns J.D. Iglehart Maintenance of p53 alterations throughout breast cancer progession Cancer Res 51 1991 2605 2610
26. R.B. Dickson M.E. Lippman Oncogenes and suppressor genes J.R. Harris M.E. Lippman M. Morrow Diseases of the Breast 1996 JB Lippincott Philadelphia 221 229
27. W.D. Dupont D.L. Page Risk factors for breast cancer in women with proliferative breast disease N Engl J Med 312 1985 145 151
28. V.L. Ernster J. Barclay K. Kerlikowske Incidence of a treatment for ductal carcinoma in situ of the breast JAMA 275 1996 913 918
29. C.J. Fabian S. Kamel C. Zalles Biomarkers predictive of short interval cancer development in high risk women The Breast Journal 3 suppl 1997 42 48
30. C.J. Fabian C. Zalles S. Kamel Prevalence of aneuploidy, overexpressed ER and EGFR in random breast aspirates of women at high and low risk for breast cancer Breast Cancer Res Treat 30 1994 263 274
31. C.J. Fabian C. Zalles S. Kamel Breast cytology and biomarkers obtained by random fine needle aspiration: Use in risk assessment and early chemoprevention trials J Cell Biochem Suppl 28 1997 101 110
32. C.J. Fabian S. Kamel C.M. Zalles Identification of a chemoprevention cohort from a population of women at high risk for breast cancer J Cell Biochem 25S 1996 112 122
33. C.J. Fabian S. Kamel B.F. Kimler Potential use of biomarkers in breast cancer risk assessment and chemoprevention trials The Breast Journal 1 1995 236 242
34. C. Fabian C. Zalles S. Kamel Biomarker and cytologic abnormalities in women at high and low risk for breast cancer J Cell Biochem 17 suppl G 1993 153 160
35. B. Fisher J. Costantino C. Redmond E. Fisher Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer N Engl J Med 328 1993 1581 1586
36. B.K. Dunn B.S. Kramer L. Ford Phase III, large-scale chemoprevention trials Hematol Oncol Clin North Am 12 1998 1019
37. F. Formelli L. Cleris E. Cavadini Analysis of fenretinide (4-HPR) effects on plasma IGF-1 levels in relation with age and chemopreventive efficacy in breast cancer patients Proc Am Assoc Cancer Res 37 1996 185
38. L.S. Freedman A. Schatxkin M.H. Shiffman Statistical validation of intermediate markers of precancer for use as endpoints in chemoprevention trials J Cell Biochem 16 suppl G 1992 27 32
39. K. Friedrichs F. Franke L. Gjörn-Wieland CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer Cancer Res 55 1995 5424 5433
40. P. Gann R. Chatterton K. Vogelsong Mitogenic growth factors in breast fluid obtained from healthy women: Evaluation of biological and extraneous sources of variability Cancer Epidemiol Biomarkers Prev 6 1997 421 428
41. G. Gasparini M. Toi M. Gion Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma J Natl Cancer Inst 89 1997 139 147
42. G.E. Goodman The clinical evaluation of cancer chemoprevention agents: Defining and contrasting phase I, II, and III objectives Cancer Res 52 1992 2752s 2757s
43. J.R. Graff J.G. Herman R.G. Lapidus E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas Cancer Res 55 1995 5195 5199
44. W.E. Grizzle R.B. Myers U. Manne Factors affecting immunohistochemical evaluation of biomarker expression in neoplasia M. Hanasek Z. Walaszek Methods in Molecular Biology, Tumor Marker Protocols vol XX 1998 Humana Press Totowa, NJ
45. W.E. Grizzle R.B. Meyers D.K. Oelschlager Prognostic biomarkers in breast cancer: Factors affecting immunohistochemical evaluation The Breast Journal 1 1995 243 250
46. A.J. Guidi S.J. Schnitt L. Fischer Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast Cancer 80 1997 1945 1953
47. C.D. Haagensen Lobular neoplasia (lobular carcinoma in situ) C.D. Haagensen Diseases of the Breast ed 3 1986 WB Saunders Philadelphia 192 241
48. Hankinson SE, Willet WC, Colditz GA, et al: A prospective assessment of plasma insulin-like growth factor levels in breast cancer risk. Proc Soc Epidemiol Res, 1997, abstract 286
49. M. Henricksson B. Luscher Proteins of the Myc network: Essential regulators of cell growth and differentiation Adv Cancer Res 68 1996 109 182
50. W. Hu M.F. Mitchell I. Boiko Decreased PCNA expression in cervical premalignant lesions after chemoprevention by αΦdifluoro-methylornithine (DFMO) Proc Am Assoc Cancer Res 37 1996 185
51. P.J. Hurlin K.P. Foley D.E. Ayer Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis Oncogene 11 1995 2487 2501
52. J.D. Jacquemier P.H. Rolland D. Vague Relationships between steroid receptor and epithelial cell proliferation in benign fibrocystic disease of the breast Cancer 49 1992 2534 2536
53. H.C. Jernstrom H. Olsson A. Borg Reduced testosterone, 17 beta-oestradiol and sexual hormone binding globulin, and increased insulin-like growth factor-1 concentrations, in healthy nulligravid women aged 19–25 years who were first and/or second degree relatives to breast cancer patients Eur J Cancer Prev 6 1997 330 340
54. A. Juu P. Bang N. Hertel Serum insulin-like growth factor I in 1030 healthy children, adolescents, and adults: Relation to age, sex, stage of puberty, testicular size, and body mass index J Clin Endocrinol Metab 78 1995 744 752
55. E. Kalkhoven B.A. Roelen J.P. de Winter Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines Cell Growth Differ 6 1995 1151 1161
56. A. Kamd N.A. Giruis J. Weaver-Feldhaus A cell cycle regulator potentially involved in genesis of many tumor types Science 264 1994 436 440
57. G.J. Kelloff C.W. Boone J.A. Crowell Development of breast cancer chemopreventive drugs The Breast Journal 1 1995 271 283
58. G.J. Kelloff C.W. Boone J.A. Crowell Risk biomarkers and current strategies for cancer chemoprevention J Cell Biochem 25 1996 1 14
59. G.J. Kelloff C.W. Boone V.E. Steele Progress in cancer chemoprevention: Perspectives on agent selection and short-term clinical intervention trials Cancer Res 54 suppl 1994 2015S 2024S
60. G.J. Kelloff C.W. Boone V.E. Steele Mechanistic considerations in chemopreventive drug development J Cell Biochem 20 suppl G 1994 1 24
61. G.J. Kelloff J.A. Crowell C.W. Boone Strategy and planning for chemopreventive drug development: Clinical development plans J Cell Biochem 20 1994 55 62
62. K. Keyomarsi N. O'Leary G. Molnar Cyclin-E, a potential prognostic marker for breast cancer Cancer Res 54 1994 380 385
63. S.A. Khan A.M. Rogers J.A. Obanda Estrogen receptor expression of benign breast epithelium and its association with breast cancer Cancer Res 54 1994 993 997
64. S.A. Khan Estrogen and progesterone receptors in benign breast epithelium The Breast Journal 1 1995 251 261
65. S.A. Khan M.A. Rogers K.K. Khurana Estrogen receptor expression in benign breast epithelium and breast cancer risk J Natl Cancer Inst 90 1998 37 42
66. E.B. King K.L. Chew L. Duarte Image cytometric classification of premalignant breast disease in fine needle aspirates Cancer 62 1988 114 124
67. J.A. Knight N.F. Boyd C. Greenberg Nutrients associated with reduction of mammographic breast density in premenopausal women in a randomized controlled dietary intervention breast cancer prevention trial Proc Am Assoc Cancer Res 39 1998 89
68. M.D. Lagios P.R. Westdahl F.R. Margolin Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures Cancer 50 1982 1309 1314
69. M.D. Lagios Heterogeneity of duct carcinoma in situ (DCIS): Relationship of grade and subtype analysis to local recurrence and risk of invasive transformation Cancer Lett 90 1995 97 102
70. M.D. Lagios Classification of duct carcinoma in situ (DCIS) with a characterization of high grade lesions: Defining cohorts for chemoprevention trials J Cell Biochem 25S 1996 108 111
71. P.A. Lambird W.M. Shelley The spatial distribution of lobular in situ mammary carcinoma JAMA 1969 210 689
72. R.D. Leek L. Kaklamanis F. Pezzella Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer Br J Cancer 69 1994 135 139
73. D. LeRoith Insulin-like growth factors and cancer Ann Intern Med 122 1995 54 59
74. U. Manne R.B. Myers C. Moron Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinomas Int J Cancer 74 1997 346 358
75. C. Markopoulos U. Berger P. Wilson Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle Br Med J 296 1988 1349 1351
76. C.J. Marshall G.B. Schumann J.H. Ward Cytologic identification of clinically occult proliferative breast disease in women with a family history of breast cancer Am J Clin Pathol 95 1991 157 165
77. L.M. Marshall D.J. Hunter J.L. Connolly Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types Cancer Epidemiol Biomarkers Prev 6 1997 297 301
78. S. Masood Cytomorphology of fibrocystic change, high risk, premalignant breast lesions The Breast Journal 1 1995 210 221
79. S. Masood E.R. Frykberg G.L. McLellan Prospective evaluation of radiologically directed fine-needle aspiration biopsy of nonpalpable breast lesions Cancer 66 1990 1480 1487
80. B.A. Miller L.A.G. Ries B.F. Hankey Breast cancer trends. Incidence, mortality and survival. SEER Cancer Statistics Review: 1973–1990 1993 National Cancer Institute Bethesda, MD NIH Publ No. 93–2789
81. R. Millikan B. Hulka A. Thor p53 mutations in benign breast tissue J Clin Oncol 13 1995 2293 2300
82. B. Modan F. Lubin E. Alfandary Breast cancer following benign breast disease—a nationwide study Breast Cancer Res Treat 46 1997 45
83. U.M. Moll G. Riou A.J. Levine Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion Proc Natl Acad Sci USA 89 1992 7262 7266
84. P. Monaghan N.P. Perusinghe R.I. Nicholson Growth factor stimulation of proliferating cell nuclear antigen (PCNA) in human breast epithelium in organ culture Cell Biol Int Rep 15 1991 561 570
85. H.L. Moses R. Serra Regulation of differentiation by TGF-beta Curr Opin Genet Dev 6 1996 581 586
86. S.J. Nass E.C. Rosfjord R.B. Dickson Regulation of cell-cycle progression and cell death in breast cancer Breast J 3 1997 15 25
87. Plenary Session. Presented at the American Society of Clinical Oncology 34th Annual Meeting. May 16–19, 1998, Los Angeles
88. H. Olsen H. Jernström P. Alm Proliferation of the breast epithelium in relation to menstrual-cycle phase, hormonal use and reproductive factors Breast Cancer Res Treat 40 1996 187 196
89. G.L. Ottesen H.P. Graversen M. Blichert-Toft Lobular carcinoma in situ of the female breast: Short-term results of a prospective nationwide study Am J Surg Pathol 17 1993 14 21
90. D.L. Page W.D. Dupont Anatomic markers of human premalignancy and risk of breast cancer Cancer 66 1990 1326 1335
91. D.L. Page W.D. Dupont L.W. Rogers M.S. Rados Atypical hyperplastic lesions of the female breast. A long-term follow-up study Cancer 55 1985 2698 2708
92. D.L. Page T.E. Kidd Jr W.D. Dupont Lobular neoplasia of the breast: Higher risk for subsequent invasive cancer by more extensive disease Hum Pathol 22 1991 1232 1239
93. O.W. Peterson P.E. Hoyer B. Van Deurs Frequency and distribution of estrogen receptor-positive cells in normal non-lactating human breast tissue Cancer Res 47 1987 5748 5751
94. N.L. Petrakis Nipple aspirate fluid in epidemiologic studies of breast disease Epidemiol Rev 15 1993 188 195
95. V. Pezzino V. Papa G. Milazzo Insulin-like growth factor I (IGF-I) receptors in breast cancer Ann NY Acad Sci 784 1996 189 201
96. M.C. Pike D.V. Spicer L. Dahmoush Estrogens, progestins, normal breast cell proliferation, and breast cancer risk Epidemiol Rev 15 1993 17 35
97. M. Pollak J. Costantino C. Polychronakos Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients J Natl Cancer Inst 82 1990 1693 1697
98. J. Pollak Effects of adjuvant tamoxifen therapy on growth hormone and insulin-like growth factor I (IGF-I) physiology S.E. Salmon Adjuvant Therapy of Cancer, VII 1993 JB Lippincott Philadelphia 43 55
99. D.N. Poller E.C. Roberts J.A. Bell p53 protein expression in mammary ductal carcinoma in situ: Relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein Hum Pathol 24 1993 463 468
100. P.L. Porter K.E. Malone P.J. Heagerty Expression of cell cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients Nat Med 3 1997 222 225
101. M.C. Posner N. Wolmark Non-invasive breast carcinoma Breast Cancer Res Treat 21 1992 155 164
102. C.S. Potten R.J. Watson G.T. Williams The effect of age and menstrual cycle upon proliferative activity of the normal human breast Br J Cancer 58 1988 163 170
103. J.L. Resnik D.B. Reichart K. Huey Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer Cancer Res 58 1998 1159 1164
104. J.M. Roberts P.L. Porter J.R. Daling Expression of cell-cycle regulatory proteins in normal and neoplastic cells: Prognostic implications of cyclin E and p27 protein levels in young women with breast cancer Proc Am Soc Clin Oncol 35 1997 41
105. J. Rosai Borderline epithelial lesions of the breast Am J Surg Pathol 15 1991 209 221
106. J.C. Sabourin A. Martin J. Baruch bcl-2 expression in normal breast tissue during menstrual cycle Int J Cancer 59 1994 1 6
107. A.F. Saftlas R.N. Hoover L.A. Brinton Mammographic densities and risk of breast cancer Cancer 67 1991 2833 2838
108. T. Said D. Medina Cell cyclins and cyclin-dependent kinase activities in mouse mammary tumor development Carcinogenesis 16 1995 823 830
109. E.R. Sauter M. Daly K. Linahan Prostate specific antigen levels in nipple aspirate fluid correlate with breast cancer risk Cancer Epidemiol Biomarkers Prev 5 1996 967 970
110. E.R. Sauter E. Ross M. Daly Nipple aspirate fluid: A promising non-invasive method to identify cellular markers of breast cancer risk Br J Cancer 76 1997 494 501
111. A. Schatzkin L.S. Freedman J. Dorgan Surrogate end points in cancer research: A critique Cancer Epidemiol Biomarkers Prev 5 1996 947 953
112. F.C. Schmitt C. Leal C. Lopes p53 protein expression and nuclear DNA content in breast intraductal proliferations J Pathol 176 1995 233 241
113. G.F. Schwartz Sub-clinical ductal carcinoma in situ of the breast: Selection for treatment by local excision alone The Breast Journal 2 1996 41 44
114. G.F. Schwartz A.S. Patchefsky S.D. Finklestein Nonpalpable in situ ductal carcinoma of the breast. Predictors of multicentricity and microinvasion and implications for treatment Arch Surg 124 1989 29 32
115. v in DCIS, invasive ductal and lobular human breast carcinomas: Virchows Arch 427 1995 365 372
116. G. Shaulsky N. Goldfinger A. Peled Involvement of wild-type p53 protein in the cell cycle requires nuclear localization Cell Growth Differ 2 1991 661 667
117. S.M. Siitonen J.J. Isola I.S. Rantala Intratumor variation in cell proliferation in breast carcinoma as determined by antiproliferating cell nuclear antigen monoclonal antibody automated image analysis Am J Clin Pathol 99 1993 26 231
118. J.S. Silva G.S. Georgiade W.G. Dilley Menstrual cycle–dependent variations of breast cyst fluid proteins and sex steroid receptors in the normal human breast Cancer 51 1983 1297 1302
119. M.J. Silverstein M.D. Lagios P.H. Craig A prognostic index for ductal carcinoma in situ of the breast Cancer 77 1996 2267 2274
120. J. Simpson D. Quan P. Clark Amplification of cyclin D1 in noninvasive breast cancer Proc Am Assoc Cancer Res 37 1996 209
121. M.H. Skolnick L.A. Cannon-Albright D.E. Goldgar Inheritance of proliferative breast disease in breast cancer kindreds Science 250 1990 1715
122. G. Soderqvist B. von Schoultz E. Tani Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle Am J Obstet Gynecol 168 1993 874 879
123. D.V. Spicer G. Ursin Y.R. Parisky Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk J Natl Cancer Inst 86 1994 431 436
124. M.W. Stanley M.J. Henry-Stanley R. Zera Atypia in breast fine-needle aspiration smears correlates poorly with the presence of a prognostically significant proliferative lesion of ductal epithelium Hum Pathol 24 1993 630 635
125. M. Stenmark-Askmalm O. Stal S. Sullivan Cellular accumulation of p53 protein: An independent prognostic factor in stage II breast cancer Eur J Cancer 30A 1994 175 180
126. B.A. Stoll Breast cancer: Further metabolic-endocrine risk markers? Br J Cancer 76 1997 1652 1654
127. P.C. Stomper P.C. Saneli M.A. VanSlyke Does tamoxifen cause mammographic changes? A longitudinal study of postmenopausal women Breast Dis 7 1994 191 195
128. 1a,b) invasive breast carcinomas Cancer Res 57 1997 1259 1263
129. F.A. Tavassoli Mammary intraepithelial neoplasia: A translational classification system for the intraductal epithelial proliferations The Breast Journal 3 1997 48 58
130. F.A. Tavassoli Y. Man Morphofunctional features of intraductal hyperplasia, atypical intraductal hyperplasia, and various grades of intraductal carcinoma The Breast Journal 1 1995 155 162
131. F.A. Tavassoli Y. Man Expression of ER, PR, p53, KI-67 in proliferative hyperplastic and malignant apocrine lesions of the breast Mod Pathol 8 1994 26A
132. F.A. Tavassoli H.J. Norris A comparison of the results of long-term followup for atypical intraductal hyperplasia and intraductal hyperplasia of the breast Cancer 65 1990 518 529
133. R. Torrisi S. Parodi F. Pensa Effect of fenretinide on the insulin-like growth factor (IGF) system in early breast cancer patients Proc Am Assoc Cancer Res 37 1996 185
134. H. Tsuda T. Fukotomi S. Hirohashi Pattern of genetic alteration in intraductal breast neoplasm associated with histological type and grade Clin Cancer Res 1 1995 261 267
135. Y. Tsutsumi S.P. Naber R.A. DeLellis neu-Oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues Hum Pathol 21 1990 750 758
136. G. Tuccari A. Rizzo M. Muscara PCNA/cyclin expression in breast carcinomas: Its relationships with Ki-67, ER, PgR immunostaining and clinico-pathologic aspects Pathologica 85 1095 1993 47 55
137. The uniform approach to breast fine-needle aspiration biopsy Diagn Cytopathol 16 1997 295 311
138. M.J. Van de Vijver J.L. Peterse W.J. Mooi Neu-protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer N Engl J Med 319 1988 1239 1245
139. C.L. Van Den Berg D. Yee Insulin-like growth factor I (IGF-I) enhances MCF-7 cell growth in vitro even in the presence of Adriamycin and taxol Proc Am Assoc Cancer Res 37 1996 220
140. van Dierdendonck J.H. Wijsman A. Keijzer Cell-cycle related staining patterns of anti-proliferative cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki-67 staining Am J Pathol 138 1991 1165 1172
141. P.J. Van Diest J.P.A. Baak Diagnostic and prognostic implications of morphometry and DNA cytometry in breast cytology J. Mouriquand Diagnosis of Non-palpable Breast Lesions: Ultrasonography Controlled Fine Needle Aspiration 1993 Karger New York 43 53
142. L. Vatten A. Kvikstad E. Nymoen Incidence and mortality of breast cancer related to body height and living conditions during childhood and adolescence Eur J Cancer 28 1992 128 131
143. O.V. Volpert V. Stellmach N. Bouch The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression Breast Cancer Res Treat 36 1995 119 126
144. R.A. Walker S.J. Dearing D.P. Lane Expression of p53 protein in infiltrating and in situ breast carcinoma J Pathol 165 1991 203 211
145. T.C. Wang R.D. Cardiff L. Zukerberg Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice Nature 369 1994 669 671
146. J.H. Ward C.J. Marshall G.B. Schumann Detection of proliferative breast disease using four quadrant fine needle aspiration J Natl Cancer Inst 82 1990 964 966
147. L.F. Watkins Decreasing expression of insulin-like growth factor binding protein-3 with progression of preneoplastic breast epithelial cell lines Proc Am Assoc Cancer Res 37 1996 218
148. M. Wrensch N.L. Petrakis E.B. King Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy Am J Epidemiol 137 1993 829 833
149. X.C. Xu N. Sneige X. Liu Progressive decrease in nuclear retinoic acid receptor β messenger RNA level during breast carcinogenesis Cancer Res 57 1997 4992 4996
150. C. Zalles B.F. Kimler S. Kamel Cytologic patterns in random aspirates from women at high and low risk for breast cancer The Breast Journal 1 1995 343 349